News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

PledPharma’s PledOx® project moves forward according to plan

June 27, 2012

PledPharma AB
Company Announcement

PledPharma’s PledOx® project moves forward according to plan

Stockholm, 2012-06-27 08:30 CEST (GLOBE NEWSWIRE) -- PledPharma (STO:PLED)
today announced that the preparations ahead of the initiation of the phase IIb
trial with PledOx® in colorectal cancer patients is moving forward as planned.
A clinical trial application to the Swedish Medical Products Agency has been
handed in and we expect an approval in August. Moreover, the opportunities to
broaden the PledOx patent protection have been strengthened by a composition of
matter patent application. 

The study has been procured in accordance with the budget at a contract
research organization and we expect to recruit the first patient in the PledOx
study during the third quarter 2012. Professor Bengt Glimelius will be the
coordinating Principal Investigator of the study. Professor Glimelius, at
Uppsala University Hospital, is a world authority within research and treatment
of cancer, especially cancer in the gastrointestinal canal. About 120 patients
will be recruited from several clinics in Europe and the US. We expect top line
results in the end of 2013. 

The recent patent application is a composition of matter patent for PledOx, in
which we describe an optimized “combination” of PLED substances in one
molecule. The application also covers the manufacturing and medical use of
PledOx and other similar substances. When these applications are approved, they
will give us a broad protection at least until 2032. 

“We have in a successful manner and in accordance with plan delivered
activities preparing the initiation of our exciting PledOx study. I am happy
and proud about what we have achieved to date and am very much looking forward
to the start of the study. We are also looking forward to working with very
experienced and qualified clinics and investigators under the leadership of
Professor Glimelius. In addition, we will strengthen our patent protection”,
says CEO Jacques Näsström. 

For further information please contact:

Jacques Näsström, CEO, cell: +46 73 713 0979

Erik Kinnman, Investor relations, cell: +46 73 422 1540

About PledPharma

PledPharma is a Swedish specialty pharma company that develops a new medicine,
PledOx®, for prevention of the severe side effects that patients develop as a
consequence of chemotherapy treatment of cancer. Many times the treatment
cannot be carried out as planned due to very difficult side effects. The
current market for supportive cancer care is some SEK 72 billion. PledOx is a
medicine within the patent protected substance class PLED, which protects the
body’s normal cells against oxidative stress. Oxidative stress is a condition
where an overabundance of harmful oxygen molecules (free oxygen radicals) has
been formed. We are also evaluating opportunities with PLED substances for
other diseases. PledPharma (STO:PLED) is listed on NASDAQ OMX First North. Erik
Penser Bankaktiebolag is the Certified Adviser. For more information, please



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10